PFE Financial Facts

Research and development expenses: 1.8B
Basic (in shares): 6.33B
See Full Income Statement

Equity attributable to noncontrolling interests: 317M
Noncurrent deferred tax liabilities: 26.32B
See Full Balance Sheet

Pfizer Inc. (PFE) Earnings

  |   Expand Research on PFE
Next EPS Date 5/5/15 *Est. EPS Growth Rate -3.6% *Last Qtr.
Average EPS % Beat Rate +2.7% Revenue Growth Rate -3.4% *Last Qtr.
Average % Move 1-Wk after EPS -2.4% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
1/29/13 Q412 $0.47$0.44 +$0.03$15.1B$14.4B = Details
2/1/11 Q410 $0.47$0.46 +$0.01$17.56B$16.97B = Details
1/31/12 Q411 $0.50$0.47 +$0.03$16.7B$16.61B = Details
11/2/10 Q310 $0.54$0.51 +$0.03N/AN/A N/A Details
1/28/14 Q413 $0.56$0.52 +$0.04$13.56B$13.35B = Details
11/1/12 Q312 $0.53$0.53 $0.00$14B$14.64B = Details
1/27/15 Q414 $0.54$0.53 +$0.01$13.1B$12.94B = Details
7/31/12 Q212 $0.62$0.54 +$0.08$15.1B$14.9B = Details